Anticoagulation control in atrial fibrillation: optimizing risks and benefits.
Alsheikh-Ali
Alawi A
AA
Estes
N A Mark
NA
D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D002986:Clinical Trials as Topic; D006801:Humans; D011787:Quality of Health Care; D018570:Risk Assessment; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin